Objective:Traditional Chinese medicine plays a significant role in the treatment of the pandemic of coronavirus disease 2019(COVID-19).Tanreqing Capsule(TRQC)was used in the treatment of COVID-19 patients in the Shang...Objective:Traditional Chinese medicine plays a significant role in the treatment of the pandemic of coronavirus disease 2019(COVID-19).Tanreqing Capsule(TRQC)was used in the treatment of COVID-19 patients in the Shanghai Public Health Clinical Center.This study aimed to investigate the clinical efficacy of TRQC in the treatment of COVID-19.Methods:A retrospective cohort study was conducted on 82 patients who had laboratory-confirmed mild and moderate COVID-19;patients were treated with TRQC in one designated hospital.The treatment and control groups consisted of 25 and 57 cases,respectively.The treatment group was given TRQC orally three times a day,three pills each time,in addition to conventional Western medicine treatments which were also administered to the control group.The clinical efficacy indicators,such as the negative conversion time of pharyngeal swab nucleic acid,the negative conversion time of fecal nucleic acid,the duration of negative conversion of pharyngeal-fecal nucleic acid,and the improvement in the level of immune indicators such as T-cell subsets(CD3,CD4 and CD45)were monitored.Results:COVID-19 patients in the treatment group,compared to the control group,had a shorter negative conversion time of fecal nucleic acid(4 vs.9 days,P=0.047)and a shorter interval of negative conversion of pharyngeal-fecal nucleic acid(0 vs.2 days,P=0.042).The level of CD3+T cells increased in the treatment group compared to the control group([317.09±274.39]vs.[175.02±239.95]counts/l L,P=0.030).No statistically significant differences were detected in the median improvement in levels of CD4+T cells(173 vs.107 counts/l L,P=0.208)and CD45+T cells(366 vs.141 counts/l L,P=0.117)between the treatment and control groups.Conclusion:Significant reductions in the negative conversion time of fecal nucleic acid and the duration of negative conversion of pharyngeal-fecal nucleic acid were identified in the treatment group as compared to the control group,illustrating the potential therapeutic benefits of using TRQC as a complement to conventional medicine in patients with mild and moderate COVID-19.The underlying mechanism may be related to the improved levels of the immune indicator CD3+T cells.展开更多
BackgroundThe holistic view of the‘The unity of man and nature’promotes the development and application of traditional Chinese medicine(TCM).Despite the absence of modern pharmacological therapies with robust effica...BackgroundThe holistic view of the‘The unity of man and nature’promotes the development and application of traditional Chinese medicine(TCM).Despite the absence of modern pharmacological therapies with robust efficacy against coronavirus disease 2019(COVID-19),TCM has exhibited potential utility for treating the disease in clinical practice.MethodsA retrospective cohort study was conducted to investigate the therapeutic effect of TCM treatment intensity(TCMTI)in patients with mild COVID-19.A total of 6120 laboratory-confirmed patients with mild COVID-19 were recruited from temporary isolation facilities.The primary outcome measure was severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)ribonucleic acid conversion time.In addition,restricted cubic spline models were employed to elucidate nonlinear relationships.ResultsThe median age(range)of the study participants was 43.0(2.0–75.0)years,with a median hospitalization duration of 9.7(4.1–22.5)days.The median time for achieving SARS-CoV-2 ribonucleic acid negativity was 6.67 days.The restricted cubic spline models revealed a remarkable nonlinear association between TCMTI and the time-to-ribonucleic acid negativity.After adjusting for potential confounders,the high TCMTI group exhibited a markedly shorter median time to SARS-CoV-2 ribonucleic acid negativity and reduced hospitalization duration(P<0.001)than the low TCMTI group.Moreover,the mean time to achieve SARS-CoV-2 ribonucleic acid negativity was shortened by 1.909 days(P<0.001)in the high-TCMTI group compared to the low-TCMTI group.ConclusionThis study suggests that early initiation and intensified use of TCM may accelerate the time required to achieve SARS-CoV-2 ribonucleic acid negativity in patients with COVID-19,bearing considerable implications for public health.展开更多
Objective: to explore the clinical value and effect of antiviral western medicine in patients with chronic hepatitis B. Methods: a retrospective study was conducted on 128 patients with chronic hepatitis B treated in ...Objective: to explore the clinical value and effect of antiviral western medicine in patients with chronic hepatitis B. Methods: a retrospective study was conducted on 128 patients with chronic hepatitis B treated in the infection department of our hospital from April 2020 to January 2021. 64 patients in the observation group were treated with antiviral western medicine and 64 patients in the control group were treated with liver protecting drugs. The effects of the two groups were compared. Results: the negative conversion rate of hepatitis B virus in the observation group was higher than that in the control group at 6, 12 and 24 weeks after treatment (P < 0.05);The negative conversion rate of hepatitis B surface antigen (HBsAg) was higher than that of the control group (P < 0.05). Conclusion: antiviral western medicine has a good effect in the treatment of chronic hepatitis B. It can effectively improve the negative conversion rate of HBsAg virus and hepatitis B virus, but it also has some limitations. Therefore, on the one hand, we should take the treatment of antiviral western medicine as the first choice for the clinical treatment of chronic hepatitis B, on the other hand, we should make a targeted analysis of the patient's condition to ensure that the treatment scheme is scientific and effective.展开更多
基金supported by Emergency Scientific Research Project of Shanghai Health Committee and Shanghai Administration of Traditional Chinese Medicine(No.2020YJ01)Shanghai Key Laboratory of Traditional Chinese Clinical Medicine(No.14DZ2273200)Shanghai Key Clinical Specialty(No.SHSLCZDZK05101)。
文摘Objective:Traditional Chinese medicine plays a significant role in the treatment of the pandemic of coronavirus disease 2019(COVID-19).Tanreqing Capsule(TRQC)was used in the treatment of COVID-19 patients in the Shanghai Public Health Clinical Center.This study aimed to investigate the clinical efficacy of TRQC in the treatment of COVID-19.Methods:A retrospective cohort study was conducted on 82 patients who had laboratory-confirmed mild and moderate COVID-19;patients were treated with TRQC in one designated hospital.The treatment and control groups consisted of 25 and 57 cases,respectively.The treatment group was given TRQC orally three times a day,three pills each time,in addition to conventional Western medicine treatments which were also administered to the control group.The clinical efficacy indicators,such as the negative conversion time of pharyngeal swab nucleic acid,the negative conversion time of fecal nucleic acid,the duration of negative conversion of pharyngeal-fecal nucleic acid,and the improvement in the level of immune indicators such as T-cell subsets(CD3,CD4 and CD45)were monitored.Results:COVID-19 patients in the treatment group,compared to the control group,had a shorter negative conversion time of fecal nucleic acid(4 vs.9 days,P=0.047)and a shorter interval of negative conversion of pharyngeal-fecal nucleic acid(0 vs.2 days,P=0.042).The level of CD3+T cells increased in the treatment group compared to the control group([317.09±274.39]vs.[175.02±239.95]counts/l L,P=0.030).No statistically significant differences were detected in the median improvement in levels of CD4+T cells(173 vs.107 counts/l L,P=0.208)and CD45+T cells(366 vs.141 counts/l L,P=0.117)between the treatment and control groups.Conclusion:Significant reductions in the negative conversion time of fecal nucleic acid and the duration of negative conversion of pharyngeal-fecal nucleic acid were identified in the treatment group as compared to the control group,illustrating the potential therapeutic benefits of using TRQC as a complement to conventional medicine in patients with mild and moderate COVID-19.The underlying mechanism may be related to the improved levels of the immune indicator CD3+T cells.
基金supported by the Project on Prevention and Treatment of COVID-19 with Traditional Chinese Medicine[grant number XGYJKY2022-09]the Intervention Effect on COVID-19 in High-Risk Groups[grant number 2022ZYLCYJ05-10]+2 种基金the Three-Year Action Plan for Promoting Clinical Skills and Innovation Ability of Municipal Hospitals[grant number SHDC2022CRS039]Shanghai Natural Science Foundation[grant numbers 22ZR1462100,23ZR1464000,23ZR1463900]the talent fund of Longhua Hospital[grant number LH001.007].
文摘BackgroundThe holistic view of the‘The unity of man and nature’promotes the development and application of traditional Chinese medicine(TCM).Despite the absence of modern pharmacological therapies with robust efficacy against coronavirus disease 2019(COVID-19),TCM has exhibited potential utility for treating the disease in clinical practice.MethodsA retrospective cohort study was conducted to investigate the therapeutic effect of TCM treatment intensity(TCMTI)in patients with mild COVID-19.A total of 6120 laboratory-confirmed patients with mild COVID-19 were recruited from temporary isolation facilities.The primary outcome measure was severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)ribonucleic acid conversion time.In addition,restricted cubic spline models were employed to elucidate nonlinear relationships.ResultsThe median age(range)of the study participants was 43.0(2.0–75.0)years,with a median hospitalization duration of 9.7(4.1–22.5)days.The median time for achieving SARS-CoV-2 ribonucleic acid negativity was 6.67 days.The restricted cubic spline models revealed a remarkable nonlinear association between TCMTI and the time-to-ribonucleic acid negativity.After adjusting for potential confounders,the high TCMTI group exhibited a markedly shorter median time to SARS-CoV-2 ribonucleic acid negativity and reduced hospitalization duration(P<0.001)than the low TCMTI group.Moreover,the mean time to achieve SARS-CoV-2 ribonucleic acid negativity was shortened by 1.909 days(P<0.001)in the high-TCMTI group compared to the low-TCMTI group.ConclusionThis study suggests that early initiation and intensified use of TCM may accelerate the time required to achieve SARS-CoV-2 ribonucleic acid negativity in patients with COVID-19,bearing considerable implications for public health.
文摘Objective: to explore the clinical value and effect of antiviral western medicine in patients with chronic hepatitis B. Methods: a retrospective study was conducted on 128 patients with chronic hepatitis B treated in the infection department of our hospital from April 2020 to January 2021. 64 patients in the observation group were treated with antiviral western medicine and 64 patients in the control group were treated with liver protecting drugs. The effects of the two groups were compared. Results: the negative conversion rate of hepatitis B virus in the observation group was higher than that in the control group at 6, 12 and 24 weeks after treatment (P < 0.05);The negative conversion rate of hepatitis B surface antigen (HBsAg) was higher than that of the control group (P < 0.05). Conclusion: antiviral western medicine has a good effect in the treatment of chronic hepatitis B. It can effectively improve the negative conversion rate of HBsAg virus and hepatitis B virus, but it also has some limitations. Therefore, on the one hand, we should take the treatment of antiviral western medicine as the first choice for the clinical treatment of chronic hepatitis B, on the other hand, we should make a targeted analysis of the patient's condition to ensure that the treatment scheme is scientific and effective.
